
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Testosterone Undecanoate
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Recipient : Lipocine
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lipocine And SPC Korea Partner to Commercialize TLANDO® in South Korea
Details : Under the term of license agreement, SPC will gain exclusive rights to market Tlando (testosterone undecanoate) in South Korea. It is indicated for the primary and hypogonadotropic hypogonadism.
Product Name : Tlando
Product Type : Hormone
Upfront Cash : Undisclosed
November 05, 2024
Lead Product(s) : Testosterone Undecanoate
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Recipient : Lipocine
Deal Size : Undisclosed
Deal Type : Licensing Agreement
